Cetuximab intensifies the ADCC activity of adoptive NK cells in a nude mouse colorectal cancer xenograft model.
Natural killer (NK) cells, discovered ~40 years ago, are believed to be the most effective cytotoxic lymphocytes to counteract cancer; however, adoptive NK cell therapyin vivohas encountered certain limitations, including a lack of specificity. The drug cetuximab can mediate antibody dependent cell mediated cytotoxicity (ADCC) activity through NK cellsin vivo, and has been approved for the first-line treatment of epidermal growth factor receptor (EGFR)-positive metastatic colorectal cancer (CRC). However, the ADCC activity of adoptive NK cells, induced by cetuximab in a nude mouse CRC xenograft model, has not been previously reported. The aim of the present study was to explore the ADCC activity of cetuximab combined with adoptive NK cells in CRC xenograft models with various EGFR expressions. The nude mouse xenograft models were established by subcutaneously injecting LOVO or SW620 cells. The mice were then randomly divided into 6 groups: Phosphate-buffered saline, cetuximab, human immunoglobulin G (hIgG), NK cells, hIgG plus NK cells and cetuximab plus NK cells. The ADCC antitumor activity was evaluated in these CRC models. The results indicated that the cetuximab plus NK cells group showed the greatest tumor inhibition effect compared with the NK cells group in LOVO xenograft tumor models with positive EGFR expression. However, the combination of cetuximab and NK cells did not show a stronger tumor inhibitory effect against the SW620 xenograft tumor models compared with the efficiency of NK cells. In conclusion, cetuximab could intensify the ADCC antitumor activity of adoptive NK cells towards CRC with an increased EGFR expression. The combination of cetuximab and NK cells may be a potential immunotherapy for metastatic CRC patients with positive EGFR expression.
Fujian Provincal Key Laboratory of Tumor Biotherapy, Teaching Hospital of Fujian Medical University, Fujian Provincal Cancer Hospital, Fuzhou, Fujian 350014, P.R. China.
Shanshan
S
Chen
Provincial Clinical College of Fujian Medical University, Fuzhou, Fujian 350014, P.R. China.
Xuechun
X
Li
Fujian Provincal Key Laboratory of Tumor Biotherapy, Teaching Hospital of Fujian Medical University, Fujian Provincal Cancer Hospital, Fuzhou, Fujian 350014, P.R. China.
Rongming
R
Chen
Fujian Provincal Key Laboratory of Tumor Biotherapy, Teaching Hospital of Fujian Medical University, Fujian Provincal Cancer Hospital, Fuzhou, Fujian 350014, P.R. China.
Mingang
M
Yin
Fujian Provincal Key Laboratory of Tumor Biotherapy, Teaching Hospital of Fujian Medical University, Fujian Provincal Cancer Hospital, Fuzhou, Fujian 350014, P.R. China.
Qiuhong
Q
Zheng
antibody dependent cell mediated cytotoxicity activity; cetuximab; colorectal cancer; epidermal growth factor receptor; natural killer cells